Why Treasury’s new inversion rules could hit the Pfizer-Allergan deal but not others
April 05, 2016 at 11:48 AM EDT
New restrictions issued by the Treasury Department Monday could throw a wrench into one particular “inversion” deal, analysts say: the proposed tie-up between Pfizer and Allergan.
